ADIPOKINE PROFILE AND METABOLIC SYNDROME IN PATIENTS WITH SIMILAR ADIPOSE TISSUE MASS AND DISTRIBUTION

  • Ivona MITU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Cristina-Daniela DIMITRIU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Cristina PREDA “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • O. MITU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Irina-Iuliana COSTACHE “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Manuela CIOCOIU “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Abstract

In order to establish more efficient ways to prevent metabolic syndrome (MetS) in clinical settings, we need to thoroughly understand the physiopathology behind this cluster of risk factors for cardiometabolic diseases. The main point of focus concerning MetS still embraces the metabolic and secretory products of the abdominal adipose tissue. Our study aims to clearly define an adipokine profile for patients with MetS and assess possible correlations between obesity parameters, biochemical markers and adipokines. Material and methods: This is a cross-sectional study, elaborated over a period of two years, which involved 104 patients divided into 2 groups: with MetS and without MetS. Patients were considered as having MetS if they presented WC > 88 cm (women) / 104 cm (men) and more than one criterion of the following: glucose ≥ 100 mg/dL, HDL < 40 mg/dL (men) / < 50 mg/dL (women), TG ≥ 150 mg/dL, SBP/DBP ≥ 130/85 mmHg. Dual-Energy X-ray Absorptiometry (DEXA) was performed to assess adipose tissue distribution. All patients underwent clinical and paraclinical evaluation, including the measurements of insulin, adiponectin and leptin. Results: Leptin levels present a strong and positive correlation with almost all obesity parameters evaluated, with or without MetS. The strongest correlation is observed for trunk fat percentage (without MetS: r=0.648, p<0.001; with MetS: r=0. 723, p<0.001). In the group of patients without MetS adiponectin level is not associated with fat percentages, whereas in the group of patients with MetS adiponectin reports a weak and positive correlation between total fat, arms fat and legs fat percentages. Adiponectin is negatively correlated with HOMA-IR and insulin in both groups, suggesting that insulin resistance is linked to the change in adiponectin levels. Patients that present MetS also report an association between HDL and adiponectin (r=0.280, p=0.02). Conclusions: Patients with MetS that did not follow prior treatment for any chronic disease and are characterized by similar adipose tissue percentage and distribution, report the following: lower adiponectin levels than patients without MetS, but still a positive association with HDL; no modification in leptin levels compared to patients without MetS; negative correlation between adiponectin and insulin resistance; strong association between leptin and adipose tissue mass.

Author Biographies

Ivona MITU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Morpho-Functional Sciences (II)

Cristina-Daniela DIMITRIU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Morpho-Functional Sciences (II)

Cristina PREDA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (II)

O. MITU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)

Irina-Iuliana COSTACHE, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)

Manuela CIOCOIU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Morpho-Functional Sciences (II)

References

1. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham heart study. Circulation 2007; 116: 39-48.
2. Mongraw-Chaffin M, Allison MA, Burke GL, et al. CT-derived body fat distribution and incident cardiovascular disease: the multi-ethnic study of atherosclerosis. J Clin Endocrinol Metab 2017; 102: 4173-4183.
3. Yamauchi T, Kamon J, Waki H et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003; 278: 2461-2468.
4. Esteve E, Ricart W, Fernández-Real JM. Adipocytokines and insulin resistance: the possible role of lipocalin-2, retinol binding protein-4, and adiponectin. Diabetes Care. 2009; 32(Suppl 2): S362-367.
5. Juergen Eckel. The Cellular Secretome and Organ Crosstalk. Chapter 2 - Adipose Tissue: A Major Secretory Organ. Academic Press; 2018.
6. Patel SB, Reams GP, Spear RM, Freeman RH, Villarreal D. Leptin: linking obesity, the metabolic syndrome, and cardiovascular disease. Curr Hypertens Rep 2008; 10: 131-137.
7. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
8. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
9. Amato MC, Giordano C, Galia M et al. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes care 2010; 33: 920-922.
10. Ntzouvani A, Fragopoulou E, Panagiotakos D, et al. Reduced circulating adiponectin levels are associated with the metabolic syndrome independently of obesity, lipid indices and serum insulin levels: a cross-sectional study. Lipids Health Dis 2016: 15: 140 / doi: 10.1186/s12944-016-0311-7.
11. Nigro E, Scudiero O, Monaco ML, et al. New insight into adiponectin role in obesity and obesity-related diseases. Biomed Res Int 2014; 2014: 658913 / doi: 10.1155/2014/658913.
12. Roy B, Palaniyandi SS. Tissue-specific role and associated downstream signaling pathways of adiponectin. Cell Biosci 2021; 11: 77 / doi: 10.1186/s13578-021-00587-4.
13. Abhijit AG, Amrita AK, Aniket AK. A potential therapeutic target for metabolic syndrome. Cytokine & Growth Factor Reviews. 2018; 39: 151-158.
14. Achari AE, Jain SK. Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction. Int J Mol Sci 2017; 18(6): 1321 / doi: 10.3390/ijms18061321.
15. Menzaghi C, Trischitta V. The adiponectin paradox for all-cause and cardiovascular mortality. Diabetes. 2018: 67(1): 12-22 / doi: 10.2337/dbi17-0016.
16. Ortega Moreno L, Lamacchia O, Salvemini L, et al. The paradoxical association of adiponectin with mortality rate in patients with type 2 diabetes: evidence of synergism with kidney function. Atherosclerosis. 2016; 245: 222-227.
17. Scarale MG, Fontana A, Trischitta V, Copetti M, Menzaghi C. Circulating adiponectin levels are paradoxically associated with mortality rate. A systematic review and meta-analysis. J. Clin. Endocrinol. Metab 2019; 104: 1357-1368.
18. Kalkman HO. An Explanation for the Adiponectin Paradox. Pharmaceuticals (Basel) 2021; 14(12): 1266 / doi: 10.3390/ph14121266.
19. Maeda N, Funahashi T, Matsuzawa Y, Shimomura I. Adiponectin, a unique adipocyte-derived factor beyond hormones. Atherosclerosis 2020; 292: 1-9 / doi: 10.1016/j.atherosclerosis.2019.10.021.
20. Yadav A, Kataria M, Saini V, Yadav A. Role of leptin and adiponectin in insulin resistance. Clinica Chimica Acta 2013; 417: 80-84.
21. Rønn PF, Andersen GS, Lauritzen T, et al. Abdominal visceral and subcutaneous adipose tissue and associations with cardiometabolic risk in Inuit, Africans and Europeans: a cross-sectional study. BMJ Open 2020; 10: e038071.
22. Korac A, Srdic-Galic B, Stancic A, Otasevic V, Korac B, Jankovic A. Adipokine signatures of subcutaneous and visceral abdominal fat in normal-weight and obese women with different metabolic profiles. Archives of Medical Science 2021; 17(2): 323-336.
23. Liao PJ, Ting MK, Wu IW, Chen SW, Yang NI, Hsu KH. Higher Leptin-to-Adiponectin Ratio Strengthens the Association Between Body Measurements and Occurrence of Type 2 Diabetes Mellitus. Frontiers in Public Health. 2021: 9: 678-681 / doi: 10.3389/fpubh.2021.678681.
24. Kang DR, Yadav D, Koh SB, Kim JY, Ahn SV. Impact of Serum Leptin to Adiponectin Ratio on Regression of Metabolic Syndrome in High-Risk Individuals: The ARIRANG Study. Yonsei Med J 2017; 58(2): 339-346.
25. Vergès B, Petit JM, Duvillard L, Dautin G, Florentin E, Galland F, Gambert P. Adiponectin is an important determinant of apoA-I catabolism. Arterioscler Thromb Vasc Biol 2006; 26: 1364-1369.
26. Uslu S, Kebapçı N, Kara M, Bal C. Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus. Exp Ther Med 2012; 4: 113-120.
27. Yamamoto Y, Hirose H, Saito I et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond) 2002; 103(2): 137-142.
28. Martin LJ, Woo JG, Daniels SR, Goodman E, Dolan LM. The relationships of adiponectin with insulin and lipids are strengthened with increasing adiposity. J Clin Endocrinol Metab 2005; 90(7): 4255-4259.
29. Marsche G, Zelzer S, Meinitzer A, et al. Adiponectin Predicts High-Density Lipoprotein Cholesterol Efflux Capacity in Adults Irrespective of Body Mass Index and Fat Distribution. The Journal of Clinical Endocrinology & Metabolism 2017; 102(11): 4117-4123.
Published
2022-06-30
Section
INTERNAL MEDICINE - PEDIATRICS